Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Tmunity Therapeutics

- PMLiVE

Gilead’s Jyseleca is given a NICE recommendation for rheumatoid arthritis

JAK inhibitor approved for use in moderate-to-severe RA

- PMLiVE

Merck’s appeal to restore hepatitis C patent verdict against Gilead fails

US Supreme Court rejects Merck’s appeal over patent dispute verdict of $2.54bn

- PMLiVE

The search for effective drug treatments for COVID-19

PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences

- PMLiVE

Kite and Oxford BioTherapeutics sign oncology research pact

Agreement will focus on five novel drug targets across a range of indications

- PMLiVE

After years of potential, cell and gene therapy is ready for the pharmaceutical mainstream

Thanks to advances in technology and new commercial viability, cell and gene therapy is finally coming of age

- PMLiVE

Gilead set to acquire hepatitis specialist MYR for €1.15bn

Acquisition will see Gilead pick up HDV treatment Hepcludex

Bayer symbol

Bayer strengthens cell and gene therapy focus with new platform

Platform builds on previous acquisition deals for AskBio and BlueRock

- PMLiVE

Gilead’s remdesivir not included in WHO’s COVID-19 drug scheme

Remdesivir not included as a priority drug, Reuters reports

- PMLiVE

Galapagos mid-stage trial failure raises concerns for Gilead deal

Investigational osteoarthritis treatment misses primary endpoint in phase 2 study

- PMLiVE

WHO trial casts doubt on remdesivir’s efficacy

Drug's developer Gilead hits back at the findings

- PMLiVE

EU announces agreement with Gilead for remdesivir supply

Drug was granted conditional marketing authorisation in the EU in July

- PMLiVE

Gilead agrees $21bn buyout of Immunomedics

Pharma company gains rights to ADC Trodelvy

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links